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ABSTRACT
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritic and ec-
zematous skin lesions. In this study, AD-like disease was induced in NCNga mice so as to evaluate the anti-
allergic effects of Vernonia amygdalina leaf extracts (VAM).
Methods: Forty NCNga mice were purchased for each of the two protocols (prophylactic and curative) of the
study. Mice were randomly divided in groups of five or six after sensitization with 5% trinitrochlorobenzene
(TNCB): aqueous extracts (VAM1), methanolic extracts (VAM2), hydrocortisone (HCT), buffer for the control
(TNCB) and the normal mice (NORM) groups.
Results: As for HCT, VAM1 and VAM2-pretreated mice showed significantly lower number of scratching be-
havior episodes (p < 0.01; vs. TNCB) following TNCB challenge. In addition, VAM1, VAM2 exerted a significant
inhibitory effect on the development of AD skin symptoms (vs. TNCB group; p < 0.001), the production of IgE,
TNF-alpha (p < 0.05), IL-5 and IFN-gamma (p < 0.01) (vs. TNCB group) and on the increase in ear thickness (p
< 0.05) in prophylactic protocol.
In the AD curative protocol, topical VAM1, VAM2 markedly improved skin lesions such as erythemahemor-
rhage (p < 0.05), scalingdryness, erosionexcoriation (p < 0.01) (vs. TNCB mice). Furthermore, a significant
decrease in ear thickness was noted in VAM1, VAM2, HCT groups (vs. TNCB group; p < 0.05) as well as the
serum total IgE, MCP-1 (p < 0.01) and eotaxin (p < 0.05). VAM2 also improved chronic eczema dermatitis skin
symptoms in a patient.
Conclusions: Results from this report suggest that VAM extracts, known as ERK pathway inhibitor, prevent
and improve atopiceczema dermatitis syndrome.
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INTRODUCTION
Environmental factors and stress have been reported
to play a role in the development and aggravation of
dermatitis. The prevalence of atopic dermatitis (AD)
is increasing, especially in industrialized countries,
and 10-20% of children worldwide are affected by AD.
It is an illness characterized by pruriginous eczema
as its main morbid process in which aggravation and
abatement are repeated, and most AD patients pre-
sent an atopic disposition. The control of inflamma-
tion, the reduction of pruritus and skin care is essen-
Allergology International. 2012;61:597-607
ORIGINAL ARTICLE
1Department of Environmental Medicine, 3Department of Derma-
tology, 5Department of Pharmacy, Kochi University Medical
School, 4Saruta Clinic of Dermatology, Kochi and 2Department of
Materials Science, Japan Advanced Institute of Science and Tech-
nology, Ishikawa, Japan.
Conflict of interest: No potential conflict of interest was disclosed.
Correspondence: Narufumi Suganuma, Department of Environ-
mental Medicine, Kochi University Medical School, Kohasu, Oko-
cho, Nankoku-city, Kochi 783−8505, Japan.
Email: nsuganuma@kochi−u.ac.jp
Received 3 November 2011. Accepted for publication 13 April
2012.
2012 Japanese Society of Allergology
DOI: 10.2332allergolint.11-OA-0393
Ngatu NR et al.
598 Allergology International Vol 61, No4, 2012 www.jsaweb.jp
Fig.　1　Distribution of total number of scratching behaviors 
following mice exposure to the chemical allergen (prophylac-
tic protocol; n = 25). *p-value less than 0.05; #p-value less 
than 0.01 (vs. TNCB mice). TNCB, 2,4,6-trinitrochloroben-
zene (buffer-treated control group); VAM1, aqueous extracts 
of Vernonia amygdalina leaf treated group; VAM2, alcoholic 
extracts of Vernonia amygdalina leaf treated group; HCT, 
hydrocortisone-treated mice; NORM, buffer-treated normal 
mice. The fi gure shows signifi cantly lower number of scratch-
ing behavior episodes in VAM1, VAM2 and HCT mice on 
days 14 and 20 (p < 0.05 and p < 0.01, respectively) as 
compared with TNCB group. Normal control mice that were 
not exposed to the hapten had markedly lower scratching 
episodes on days 14 and 20 (p < 0.01, vs. TNCB group).
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tial in the treatment of AD.1-4 T cells and eosinophils
are also thought to play a major role in the patho-
genesis of the disease. In human, skin lesion in AD
reveals a mononuclear cells infiltrate consisting of ac-
tivated CD4+ T cells and most AD patients have in-
creased serum levels of IgE antibodies against many
kinds of allergens.5,6
Although evidence suggests that the development
and pathogenesis of AD are associated with immu-
nologic reaction such as type I allergic reaction,7,8 a
significant increase in number of cells expressing the
Th1 cytokines, IFN-γ can be observed in some
chronic AD conditions.4,7-11
Vernonia amygdalina (VAM) is an edible African
plant whose leaves are used in traditional medicine
by some Congolese villagers to relieve cough and
hemorrhoids. It has been reported that the plant ex-
tracts have an antioxidant, anti-inflammatory and anti-
tumor activities.11-13 Up to now, there have been no
published researches on the beneficial effects of
VAM extracts on skin allergy.
NCNga (NC) mice are a species that spontane-
ously develop eczematous AD-like skin lesions when
kept under conventional care and have been used in
several studies related to AD induction in mice.6 In
this experiment, NCNga mice were used to evaluate
the prophylactic and curative effects of VAM extracts
in a murine model of atopic dermatitis-like disease.
METHODS
NCNga MICE
In total, eighty inbred male NCNga mice (6 weeks of
age) were purchased from Japan SLC (Hamamatsu,
Shizuoka, Japan) for this study. Two separate experi-
ments were conducted in 2010 and 2011, the prophy-
lactic and curative protocols for atopic dermatitis-like
disease. Forty animals were used for each protocol.
Mice were always housed under conventional condi-
tions at the animal facility of Kochi University Medi-
cal School in filter-topped macrolon cages, with a bed-
ding of wood chips (temperature: 23℃; 50-60% of rela-
tive humidity; 12-h lightdark cycle). A standard lab
chow was provided with acidified tap water that was
taken ad libitum by the animals. The research ad-
hered to the animal facility guidelines of Kochi Medi-
cal School (C000144). Mice were maintained until
they were 7 weeks old (-20-24 g body wt) before their
use in the study.
VERNONIA AMYGDALINA EXTRACTS PRE-
PARATION
Vernonia amygdalina species are believed to differ ac-
cording to their origins. The plant is cultivated in
west Africa region where its leaves are used in ethno-
medicine and also as vegetable and drink; however,
in the Democratic Republic of Congo, it often grows
as a wild plant.
Our preliminary study with the plant, realized at Ja-
pan Advanced Institute of Science and Technology
(JAIST), consisted in high performance liquid chro-
matography (HPLC) and gass chromatography mass
spectrometry (GC-MS) analyses of the leaf extracts
which showed that the alcoholic extracts’ main com-
pounds are terpenoids (sesquiterpenes) and lipids,
whereas the water extracts are mainly composed of
polyphenols (flavonoids), saponins and also lipids.
The most active terpene and flavonoid in the extracts
have been reported to be vernodalin and dicaffeoyl
quinic acid and its derivates, respectively.11,12
For this study, fresh leaves of Vernonia amygdalina
leaves were harvested in a garden in Kinshasa,
Democratic Republic of Congo, by one of the authors
of this report; they were rinsed with distilled water
and sorted to remove dead leaves and debris. Leaves
were sun-dried, milled so as to get a course powder
(1.2 Kg in total). For the preventive and curative pro-
tocols of the experiment, two separate samples of
VAM powder (100 g each) were separately mixed
and homogenized with hot distilled water for VAM1
group (water extraction), and methanol for VAM2
group (alcoholic extraction). The mixtures were al-
lowed to stand on the mixer for 24 hours after which
they were filtered. The filtrates were then placed in a
rotary evaporator, yielding 35.1 g and 33.2 g (nearly
35% and 33% yields of crude extracts) for the alcoholic
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Table　1　Mean severity score for ear skin symptoms on day 8-14-20 of AD prophylactic protocol according to mice group (n = 
25; mean +/- SD)
Symptom Day VAM1 VAM2 HCT TNCB NORM
Scaling/dryness  8 0.00 0.00 0.00 0.00 0.00
14 0.25 0.00 0.25 1.50 0.00
20 1.00 0.50 1.00 2.50 0.00
p < 0.001 p < 0.001 p < 0.001 ― ―
Erythema/hemorrhae  8 0.00 0.00 0.00 0.00 0.00
14 0.25 0.00 0.00 1.50 0.00
20 0.75 0.25 0.50 2.75 0.00
p = 0.059 p < 0.001 p < 0.001 ― ―
Excoriation/erosion  8 0.00 0.00 0.00 0.00 0.00
14 0.50 0.00 0.00 2.00 0.00
20 0.50 0.00 0.25 2.50 0.00
p = 0.001 p < 0.001 p < 0.001 ― ―
p, p-value; VAM1, aqueous extract of Vernonia amygdalina group; VAM2, alcoholic extract of Vernonia amygdalina group; TNCB, nega-
tive control group; NORM, normal control group.
Fig.　2　Pretreatment with Vernonia amygdalina extracts in-
hibits the increase in ear thickening following challenge to 
the hapten. *p-value less than 0.05 (vs. TNCB). TNCB, trini-
trochlorobenzene; VAM1, aqueous extracts of Vernonia 
amygdalina leaf; VAM2, alcoholic extracts of Vernonia amyg-
dalina leaf; HCT, hydrocortisone; NORM, normal control. 
The fi gure shows that, despite repeated challenges to the 
chemical allergen, both VAM1 and VAM2, as well as HCT, 
signifi cantly prevented the increase in ear thickness as com-
pared with TNCB mice (p < 0.05). In addition, no statistically 
signifi cant difference was observed between VAM1 and 
VAM2 groups (p > 0.05).
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Fig.　3　Serum level of total IgE (prophylactic protocol; n = 
25; mean +/- SD). #p-value less than 0.01. ND, not detected; 
TNCB, buffer-treated control group; VAM1, aqueous extract 
of V. amygdalina treated group; VAM2, methanolic extract of 
V. amygdalina treated group; HCT, hydrocortisone-treated 
group; NORM, buffer-treated normal control group. The fi g-
ure shows that serum level of total IgE was signifi cantly low-
er in VAM1, VAM2, and HCT-pretreated groups as compared 
with TNCB group (p < 0.01). The serum IgE level was not 
detectable in normal mice.
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and aqueous extracts, respectively. The solid resi-
dues were mixed with distilled water for the experi-
ment and kept in the refrigerator at 4℃. The solution
used in the experiments was 7 mgml for both aque-
ous (VAM1) and alcoholic extracts (VAM2).
MICE SENSITIZATION, AD INDUCTION AND
TREATMENT
For each of the experimental protocols, NCNga
mice were randomly divided into groups of five or six
(for the prophylactic and curative protocols, respec-
tively) a week after sensitization with 5% trinitro-
chlorobenzene. In this report, five mice groups are
considered, including VAM1, VAM2, hydrocortisone
(HCT), and buffer-treated trinitrochlorobenzene
(TNCB) and normal control (NORM) for a total of 25
mice for the prophylactic protocol and 30 mice for the
curative protocol. Data related to another plant mate-
Ngatu NR et al.
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Fig.　4　Serum cytokine levels (preventive protocol; n = 25; mean +/- SD). #p-value less than 0.01; *p-val-
ue less than 0.05. ND, not detected; VAM1, aqueous extract of Vernonia amygdalina leaf treated mice; 
VAM2, methanolic extract of Vernonia amygdalina leaf treated mice; HCT, hydrocortisone-treated mice; 
TNCB, 2,4,6-trinitrochlorobenzene (buffer-treated control group); NORM, buffer-treated normal control 
mice. The fi gure shows signifi cantly lower levels of serum TNF-α in VAM1, VAM2 and hydrocortisone-pre-
treated mice groups (p < 0.05; vs. TNCB group) (a). Similarly, markedly lower levels of IFN-γ (b) and IL-5 
were found in VAM1, VAM2 and HCT groups (p < 0.01; vs. TNCB group). The serum levels of IL-4 were 
too low and not detectable in VAM1, VAM2, Hydrocortisone-pretreated groups and also the normal mice 
group (c).
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rial used in this study are reported elsewhere.
The chemical allergen used in this study to induce
atopic dermatitis-like skin lesions in NCNga mice
was 2,4,6-trinitrochlorobenzene (Nacalai Tesque,
Kyoto, Japan); it was used after recrystalization with
ethanol. To sensitize mice, 150 μl of 5% TNCB was ap-
plied epicutaneously on mice abdomens at 7 weeks of
age as previously described.6 A week later (on day 8)
after initial sensitization, the external areas of both
right and left ears were applied once with 15 μl of 1%
TNCB solution, dissolved in acetone and olive oil
mixture (4 : 1), then repeatedly once every three days
from the following week to induce atopic dermatitis-
like skin lesions as described in the experimental pro-
tocol (Supplementary Fig. 1 available at the online
journal site). During TNCB challenge period, mice
were usually anesthetized with diethyl ether by inha-
lation.
In the AD prophylactic protocol, just after being
anesthetized, mice were then pretreated with respec-
tive treatments: VAM1, VAM2, hydrocortisone or
buffer for TNCB and NORM groups. Thirty minutes
later, 15 μl of 1% TNCB was applied on mice ears so
as to induce itch and AD-like skin lesions; whereas in
the AD curative protocol all mice were first chal-
lenged to 15 μl of 1% TNCB until they develop atopic
dermatitis-like skin lesions (day 8 to day 20); thereaf-
ter, they were treated, from day 21 to 29, with VAM1,
VAM2, hydrocortisone or buffer according to mice
groups. For both the preventive and curative proto-
cols, 20 μl of each treatment (VAM1, VAM2, hydro-
cortisone, buffer) was applied epicutaneously on mice
ears. Animals were always kept in separated cages
throughout the experiment.
EAR THICKNESS MEASUREMENT AND SC-
RATCHING BEHAVIOR EPISODES COUNT
Ear thickness, which expresses the severity of inflam-
matory process and edema in mouse ear, was meas-
ured with the use of a digimatic (electronic) caliper
Vernonia amygdalina and Skin Allergy
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Fig.　5　Mean severity score for AD skin lesions in treated mice (AD curative protocol; n = 30; mean +/- SD). 
*p-value less than 0.05; #p-value less than 0.01 (vs. TNCB). VAM1, aqueous extract of Vernonia amygdalina 
leaf treated mice; VAM2, methanolic extract of Vernonia amygdalina leaf treated mice; HCT, hydrocortisone-
treated mice; TNCB, 2,4,6-trinitrochlorobenzene (buffer-treated control group); NORM, buffer-treated normal 
control mice.The fi gure shows a signifi cant reduction of the mean severity score for scaling/dryness (p < 0.01) 
(a), erythema/hemorrhage (p < 0.05) (b) and erosion/excoriation (p < 0.01) (c) in VAM1 and VAM2 mice 
groups after 10 days (5 applications) of treatment as compared to buffer-treated negative control (TNCB) mice. 
Similar trend was observed in hydrocortisone mice.
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IP66 (Mitutoyo, Kawasaki, Japan). Scratching behav-
ior were recorded using playback of videotaped im-
ages, taken with the use of digital video camera GR-
DVL7 (Victor, Yokohama, Japan) and the number of
scratching episodes that occurred within the first
thirty minutes, following 1%TNCB challenge, was
counted on days 8, 14 and 20 for each mouse in the
prophylactic protocol, and on days 21, 23, 25, 27 and
29 in the curative protocol. They are expressed as
mean +- SD in the results section. Normal mice were
exposed to buffer instead of TNCB.
HEMATOXYLIN AND EOSIN STAINING (HE
STAIN) AND BIOLOGICAL MARKERS MEAS-
UREMENT
On day 20 of the prophylactic protocol, skin biopsy
specimen from left ears of mice (7 mm of longest di-
mension) were taken and samples were fixed in 10%
formalin, embedded in paraffin, sectioned at 10 μm
and stained with hematoxylin and eosin (HE). To ex-
amine the specimens, light microscope BX60 from
Nikon, Tokyo, Japan, was used at ×100 magnification.
Blood samples were drawn after sacrificing mice with
the use of diethyl ether by inhalation, for the meas-
urement of serum levels of immunoglobulin E (IgE),
Th-1 cytokines (TNF-α, IFN-γ) ανδ Tη-2 χψτοκινεσ
(IL-4, IL-5). In the curative protocol, serum levels of
total IgE and CC-chemokines such as MIP-1 and eo-
taxin were measured. All those markers were as-
sayed with the use of respective ELISA kits for mice
and in accordance with the makers’ instructions.
EVALUATION OF CLINICAL SEVERITY OF DER-
MATITIS
The severity of skin lesions was evaluated macro-
scopically using the following scoring procedure as
previously described7 (0, no symptoms; 1, mild; 2,
moderate; 3, severe) for each of the following symp-
toms and signs: drynessscaling, erythemahemor-
rhage, excoriationerosion. Symptoms were recorded
three times, using purposely prepared excel forms,
on days 8, 14 and 20 in the prophylactic protocol, and
Ngatu NR et al.
602 Allergology International Vol 61, No4, 2012 www.jsaweb.jp
Fig.　6　Serum levels of total MCP-1 (a), eotaxin (b) and total IgE (c) in treatment and control mice (AD 
curative protocol; n = 30; mean +/- SD). *p-value less than 0.05; #p-value less than 0.01. ND, not detect-
ed; VAM1, aqueous extract of Vernonia amygdalina leaf treated group; VAM2, methanolic extract of Ver-
nonia amygdalina leaf treated group; HCT, hydrocortisone; TNCB, 2,4,6-trinitrochlorobenzene (buffer-
treated control group); NORM, buffer-treated normal mice. The fi gure shows signifi cantly reduced levels 
of serum MCP-1 (p < 0.001), total IgE (p < 0.001) and eotaxin (p < 0.05) in VAM1, VAM2 and hydrocorti-
sone-treated mice groups. The serum level of total IgE was too low and not detected in the normal mice.
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on days 21, 24, 25, 27 and 29 in the curative protocol.
CASE OF ATOPICECZEMA DERMATITIS IN A
17 YEARS OLD STUDENT TREATED WITH VAM
A 17-year-old albino boy with a chronic atopicec-
zema dermatitis was consulted by our medical team
during a dermatological screening and care project in
the western province of Bas-Congo, Democratic Re-
public of Congo. He was one of the 523 school chil-
dren and staffs presenting with skin disorders. In this
report, we include a brief description of the patient
skin condition and the outcome of VAM therapy.
STATISTICAL ANALYSIS
All data from different mice groups were expressed
as mean ± SD. Statistical differences in scratching be-
havior episodes, the severity of symptoms, serum lev-
els of cytokines, chemokines and IgE were assessed
by Dunnett test following one way analysis of vari-
ance. On the other hand, differences in ear thickness
between mice groups [comparing values obtained af-
ter starting treatment to baseline values (day 8 for
prophylactic protocol and day 21 for curative proto-
col)] using Fisher’s exact test. P-values less than 0.05
were considered statistically significant. All analyses
were performed using Stata software version 10 (Sta-
taCorp, Texas, USA).
RESULTS
VAM EXTRACTS PREVENT THE DEVELOPMENT
OF ATOPIC DERMATITIS-LIKE DISEASE IN MICE
Effect of Topical Administration of VAM Extracts
on Scratching Behavior
The total number of videotaped scratching behavior
episodes for each group was counted on day8, day14
and day20. Mice pretreated with VAM1, VAM2 and
hydrocortisone showed significantly lower numbers of
scratching behavior episodes on day 14 (p < 0.05) and
day 20 (p < 0.01) of the prophylactic protocol as com-
pared with TNCB group. Normal control mice that
were not exposed to the hapten had markedly lower
scratching episodes on days 14 and 20 (p < 0.01). In
addition, VAM1 and VAM2 groups had lower num-
bers of scratching episodes as compared with
hydrocortisone-pretreated mice, but not significantly
(p > 0.05) (Fig. 1). Furthermore, no statistically sig-
nificant difference was observed between VAM1,
VAM2-pretreated mice groups (p > 0.05).
Vernonia amygdalina and Skin Allergy
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Fig.　7　Trend in ear thickness changes in treated mice from 
day 21 to day 29 of the experiment (n = 30; mean +/- SD). 
*p-value less than 0.05; #p-value less than 0.01. VAM1, 
aqueous extract of Vernonia amygdalina leaf treated mice; 
VAM2, alcoholic extract of Vernonia amygdalina leaf treated 
mice; HCT, hydrocortisone-treated mice; TNCB, 2,4,6-trini-
trochlorobenzene (buffer-treated control group); NORM, buf-
fer-treated normal control mice. The fi gure shows an inhibit-
ing effect of hydrocortisone, the alcoholic and aqueous 
extracts of Vernonia amygdalina leaf on the increase in ear 
thickness that could result from repeated exposure to TNCB. 
A signifi cantly reduced ear thickness was observed in VAM2, 
VAM1 and HCT-treated mice on day 25, day 27 (p < 0.05) 
and day 29 (p < 0.01) of treatment as compared with buffer-
treated TNCB group. No signifi cant difference was observed 
between treatment groups [VAM1, VAM2, HCT; (p > 0.05)].
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Topical Application of VAM Extracts Inhibits the
Development of AD Skin Lesions and Prevents
the Increase in Ear Thickness in Mice Following
Repeated Challenges to the Hapten
NCNga strain of mice has also been reported to de-
velop atopic dermatitis-like skin lesions following re-
peated application of TNCB. In the preventive proto-
col of the study, TNCB-challenged mice developed
AD-like lesions within the second week after initial
sensitization, showing hypertrophy and hyperkerato-
sis of the epidermis. The severity of skin symptoms
increased gradually during the experiment period in
TNCB (control) mice. Conversely, no macroscopi-
cally visible skin lesions were observed in VAM1 and
VAM2-pretreated mice during the second week post
initial sensitization (vs. TNCB group; p < 0.001) (Ta-
ble 1) and no significant difference was observed be-
tween VAM2-pretreated mice and the normal mice
group (p > 0.05). VAM2 and HCT groups showed
markedly lower severity score for all skin lesions
throughout the experiment (prophylactic protocol);
however, in regard to the severity of erythemahem-
orrhage, the difference between VAM1 and TNCB
groups was no statistically different (p = 0.059) at the
end of experiment.
Regarding the trend in ear thickness, after re-
peated challenge to the chemical allergen, VAM1,
VAM2 and HCT significantly prevented the increase
in ear thickness as compared with TNCB mice (p <
0.05), and no statistically significant difference was
observed between VAM1 and VAM2 groups (p >
0.05) (Fig. 2).
Effect of Topical Administration of V. amygdalina
Extracts on Serum Levels of Total IgE, TNF-α
IFN-γ, IL-4 and IL-5 in Mice
The serum titers of immunoglobulin E (IgE) were
significantly lower in VAM1, VAM2, and hydrocorti-
sone-pretreated groups as compared with TNCB
group (p < 0.01) and no statistical difference was ob-
served between VAM1, VAM2 and hydrocortisone-
pretreated groups (p > 0.05) (Fig. 3).
On the other hand, the serum level of TNF-α was
significantly lower in VAM1, VAM2 and HCT (p <
0.05) groups as compared with TNCB mice (Fig. 4a).
In addition, the levels of IFN-γ and IL-5 were also
markedly lower in VAM1, VAM2 and HCT groups (p
< 0.01; vs. TNCB group) (Fig. 4b, c). However, the
serum levels of IL-4 were too low and undetectable in
VAM1, VAM2 and Hydrocortisone-pretreated groups
VAM EXTRACTS AMELIORATES ATOPIC DER-
MATITIS-LIKE DISEASE IN MICE
VAM Extracts Improve Skin Lesions
After inducing AD-like skin lesions in all mice (cura-
tive protocol), they were treated the other day with
VAM1, VAM2, hydrocortisone or buffer, according to
treatment groups for a total five applications (10
days). Both VAM1 and VAM2, as well as hydrocorti-
sone, markedly improved erythemahemorrhage (p <
0.05), scalingdryness and erosionexcoriation (p <
0.01) as compared with TNCB group (Fig. 5a, b, c).
In addition, though VAM2 mice seemed to show a
good and quick improvement, no statistically signifi-
cant difference was observed when compared with
hydrocortisone group, and also between VAM2 and
VAM1 groups (p > 0.05).
VAM Extracts Reduce the Serum Levels of CC-
Chemokines Eotaxin and MCP-1 and Total IgE
MCP-1 and eotaxin are CC-chemokines that play a
role in the migration of monocytes and eosinophils to
the inflammation site. In this study, treatment with
VAM1, VAM2, as well as hydrocortisone, signifi-
cantly reduced the serum levels of MCP-1 (p < 0.01),
eotaxin (p < 0.05) and IgE (p < 0.01) (Fig. 6a, b, c).
No statistically significant difference was noted in
terms of serum levels of MCP-1, eotaxin and IgE be-
tween both VAM extracts, and also between VAM ex-
tracts and hydrocortisone-treated atopic mice (p >
0.05).
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Fig.　8　Macroscopic ear skin lesions and histological features (HE stain) of auricular skin specimen 
(×100 magnifi cation) of representative mice after 10 days of treatment (curative protocol; n = 30). 
HCT, hydrocortisone-treated group; VAM1, aqueous extracts of Vernonia amygdalina treated mice; 
VAM2, alcoholic extracts of Vernonia amygdalina treated mice; TNCB, buffer-treated control mice; 
NORM, buffer-treated normal mice. Noticeable severe skin lesions with hyperkeratosis and an intense 
infl ammatory cells infi ltration in ear skin specimens were observed in buffer-treated TNCB mouse, 
while those processes were markedly inhibited by VAM1, VAM2 and hydrocortisone treatment. In ad-
dition, a re-epithelization of the skin was obviously observable in VAM-treated mice ear specimen.
Right ear Left ear HE stain image
TNCB
mouse
VAM1
mouse
VAM2
mouse
HCT mouse
Trend in Ear Thickness Changes in Treated Mice
from Day 21 to Day 29 of Experiment (Curative
Protocol)
Exposure to the hapten (TNCB) induces the increase
in the ear thickness in mice. We measured the ear
thickness in mice from day 21 to day 29 of treatment.
A marked decrease in ear thickness was observed in
VAM2, VAM1 and HCT-treated mice on day 25, day
27 (p < 0.05) and day 29 (p < 0.01) of the experiment
as compared with TNCB group. On the other hand,
no significant difference was observed between
VAM1, VAM2 and HCT groups (p > 0.05) (Fig. 7).
VAM Extracts Reduce Inflammatory Cells Infiltra-
tion to Mice Ears
The 10-day period of VAM and hydrocortisone treat-
ment markedly reduced inflammatory cells infiltra-
tion compared to buffer-treated TNCB mice (Fig. 8).
While noticeable collagen deposition in the extra-
cellular matrix, hemorrhagic zones and disruption of
ear skin barrier were still present in buffer-treated
TNCB mice at the end of the experiment, a marked
improvement of these processes was observed in
VAM1, VAM2 and hydrocortisone-treated mice.
Taken together, these changes suggest that
VAM1, VAM2 and HCT treatments improved the
hapten- induced ear skin allergic inflammation in
mice.
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Fig.　9　Case of eczema dermatitis in a 17-year-old boy. EASI, eczema area and severity in-
dex. The fi gure shows marked improvement of scaling, edema, incrustation and erythematous 
lesions on day 21 of VAM treatment.
VAM 2
3 weeks later
Day 1
Eczema dermatitis in a 17-year-old albino boy
THE ALCOHOLIC EXTRACTS OF VERNONIA
AMYGDALINA LEAF IMPROVE ECZEMA DER-
MATITIS SYNDROME IN A 17 YEARS OLD BOY
The patient has been suffering from eczema dermati-
tis for several months and taken care at a local medi-
cal center. He presented with itchy erythematous
skin lesions and was treated with the use of topical
zinc oxide ointment and some topical steroid prepara-
tions such as betamethasone dipropionate cream
which was available at the medical center; however,
his skin condition did not improve. In December
2010, the patient consulted our medical team and pre-
sented with severe itchy and erythematous skin with
incrustation, edema, lichenification and scaling on
neck and shoulder areas for an estimated eczema
area and severity index (EASI) of 7.8 on day 1;
scratch markings and lichenification were also notice-
able. A written informed consent was obtained from
the patient’s mother, as for other patients taken care
during a dermatological screening conducted in
schools of the province of Bas-Congo, Democratic re-
public of Congo.
The treatment with VAM relieved itch completely
within the second week and improved the severity of
the disease (EASI = 0.7) on day 21, as shown on Fig-
ure 9. For more about a year since this treatment, the
patient did not develop similar skin condition.
DISCUSSION
AD-like skin lesions in NCNga mice are similar to
those of human atopic dermatitis, showing various
grades of signs and symptoms such as erythema and
hemorrhage, followed by edema, superficial erosion,
deep excoriation and skin dryness. Although it oc-
curs primarily in childhood, AD can persist or start in
adulthood.14
In the prophylactic protocol of our study, after sen-
sitization with 5% TNCB, AD-like disease was induced
in mice using a repeated exposure to 1% TNCB on
dorsal region of both left and right ears. Despite the
repeated application the chemical allergen, VAM1
and VAM2 inhibited the development of AD skin le-
sions and on the increase of ear thickness. Both the
aqueous and alcoholic extracts showed a relatively
better effect regarding inhibition of itch than did hy-
drocortisone, as animals pretreated with those ex-
tracts showed significantly lower number of scratch-
ing behavior episodes than hydrocortisone-pretreated
mice.
The serum level of total IgE, one of the markers of
allergic inflammation, was significantly lower in V.
amygdalina extracts pretreated mice. As for HCT,
both VAM1 and VAM2 significantly inhibited the pro-
duction of inflammatory markers such as Th2 cytoki-
nes, IL-4 and IL-5; and Th1 cytokines, IFN-γ and TNF-
α in the prophylactic protocol of the study.
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In the curative protocol, VAM1 and VAM2 mark-
edly reduced the severity of skin lesions (scaling
dryness, erythemahemorrhage, erosionexcoria-
tion) in atopic mice. In addition, as for HCT, VAM1
and VAM2 also significantly decreased the serum lev-
els of IL-4, IL-5 and CC-chemokines such as eotaxin
and MIP-1, which seemed to reflect the histopha-
tological features (reduction of inflammatory cells in-
filtration, skin barrier disruption) observed in VAM-
treated mice.
Th2 cytokine IL-5 is believed to activate eotaxin,
and this chemokine induces eosinophilic infiltration
in allergic inflammation; on the other hand, eosino-
philia is often accompanied by IgE overproduc-
tion.15,16 The inhibition of the release of eotaxin
thanks to inhibition or reduction of IL-5 production in
one side, and the inhibition and reduction of IgE pro-
duction by VAM therapy that were observed in this
study may explain the anti-inflammatory effects dis-
played by the extracts in VAM-treated mice. It has
been previously reported that VAM extracts possess
ERK pathway inhibitory activity12,13; and that could
justify the anti-allergic effect demonstrated in these
animal experiments. This anti-allergic effect is mainly
attributable to vernodalin, the most potent anti-
inflammatory and antitumor terpenoid compound
found in vernonia amygdalina leaf extract.17 Fur-
themore, the improvement of eczema dermatitis skin
signs and symptoms observed in the case described
in the results section of this manuscript, after VAM
treatment, reflects that of the animal experiment.
In recent years, considerable attention has been fo-
cused on dietary and medicinal phytochemicals that
inhibit, reverse or retard diseases caused by oxida-
tive and inflammatory processes, anti-allergic foods
ingredients have been attracting attention such as lac-
tic bacteria and plant polyphenols.18-22 Vernonia
amygdalina is grown in Africa and it has been re-
ported its leaf extracts exert hepatoprotective and an-
tioxidant activities in animals. The plant is used as a
vegetable or drink mostly in western African coun-
tries and its leaf is rich in flavonoids and sesquit-
erpene lactones. Flavonoids and sesquiterpenes lac-
tones in the plant’s leaf are believed to be responsible
of the anti-inflammatory activity.23,24 Our very recent
study in allergic patients has proven the safety of
VAM extracts.25 Further investigations to identify its
major active components that display anti-allergic ac-
tivity are being finalized. In our experiments, though
the alcoholic extracts showed relatively better effects
for a number of parameters evaluated, the difference
between both extracts was in general not statistically
different.
In conclusion, the present study is the very first
that shows the beneficial effects of Vernonia
amygdalina leaf extracts on skin disorders; it demon-
strates both the prophylactic and curative effects of
Vernonia amygdalina leaf extracts on atopic
dermatitis-like disease in mice. Our results suggest
that VAM extracts, known as ERK pathway inhibitor,
exert prophylactic and curative effects on AD possi-
bly through this pathway inhibition and down regula-
tion of IgE production.
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